ATACH-2 Trial

The ATACH-2 study was published in 2016 and investigated intensive blood pressure reduction in patients with acute intracerebral hemorrhage.

ATACH-2 Trial study population
Overview of the study population in the ATACH-2 Trial. Figure adapted from the original publication of the ATACH-2 Trial from 2016.

ATACH-2 Trial Figure 1
Figure adapted from the original publication of the ATACH-2 Trial.

ATACH-2 Trial Figure 2
Figure adapted from the original publication of the ATACH-2 Trial.

Interpretation by the Study Authors

The treatment of participants with intracerebral hemorrhage to achieve a target systolic blood pressure of 110 to 139 mm Hg did not result in a lower rate of death or disability than standard reduction to a target of 140 to 179 mm Hg.1

References


    Editorial transparency

    Authorship & revisions

    Who created and updated this article, and which changes are documented.

    Article created by
    Last edited:
    on
    Revision history
    4 edits · 1 contributor
    Author list:
    Show revision history 4 entries

    4 edits by 1 author

    Edit · Alaric Steinmetz · (+3 −3)

    No content change recorded

    Edit · Alaric Steinmetz ·

    No content change recorded

    Edit · Alaric Steinmetz · (+5 −5)
    • Text changed: “The ATACH-2 study was published in 2016 and investigated intensive blood pressure lowering in patients with acute [intracerebral hemorrhage](\/lexikon\/intrazerebralblutung-icb).”“The ATACH-2 study was published in 2016 and investigated intensive blood pressure reduction in patients with acute [intracerebral hemorrhage](\/lexikon\/intrazerebralblutung-icb).”
    • Text changed: “## Interpretation by the study authors {#interpretation}”“## Interpretation by the Study Authors {#interpretation}”

    Article created on · Alaric Steinmetz

    Image viewer

    Image

    Open original